Categories AlphaGraphs, Leisure & Entertainment, Technology

Disney looks rock solid, thanks to a powerful 2019 theatrical line-up

A couple of weeks back, Disney (DIS) released the first theatrical trailer of Avengers: Endgame and movie buffs can’t stop speculating about the fate of Tony Stark and others. Thanks to a highly successful Infinity Wars, expectations are sky high going into the movie’s release, which is scheduled for April 26, 2019.

Adding to the tizzy is the release of yet another Marvel movie – Captain Marvel, which is hitting screens on International Women’s Day on March 8.

Besides these two big movies, Disney has an interesting line-up for 2019, including The Lion King, Toy Story 4, Frozen 2 and Star Wars Episode 9. In short, Disney’s Studio Entertainment business, which makes up more than a quarter of its total revenue, is all set to make its cash register ringing next year.

This year proved that Disney has the manpower and talent to pull audiences into theatres. Three out of the top five grossing movies – Black Panther, Avengers: Infinity War and Incredibles 2 – came from Disney’s production studios, according to Comscore. The films also form the top three grossing movies of the year.

Disneys studio entertainment business YoverY revenue growth

In 2018, more than a quarter of all ticket sales in the US accounted for movies coming from the House of Mouse. In comparison, Universal Studios accounted for 15% of all US ticket sales, while Warner Bros represented 12%. Sony came in at high single digit.

The company also had a wonderful run at the box office, collecting almost $3 billion from the US alone this year.

The Bob Iger-led firm is giving high expectations, both to investors and movie-buffs. All are now waiting for a repeat of 2018.

 

Follow our Google News edition to get the latest stock market, earnings, and financial news at your fingertips 

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top